Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Obesity is now recognized as a chronic, relapsing disease associated with increased risk of more than 200 conditions, including [3]: Type 2 diabetes Cardiovascular disease Obstructive sleep apnea Certain cancers Increased overall mortality Beyond individual patient risk, the system-level burden is substantial
Many people feel fine at first, then hunger surges later In the STEP 1 extension, participants regained about two thirds of prior weight loss in the year after stopping A 2026 BMJ meta-analysis estimated average regain of roughly 0.4 kg per month after stopping weight-loss medications, with return toward baseline projected within 1.5 to 1.7 years The same meta-analysis found no evidence that more intense behavioural support during treatment meaningfully changed the rate of regain after stopping Weight regain is often accompanied by reversal of cardiometabolic improvements, not just scale change Summary Stopping semaglutide should be understood as a biology handoff
Rather than enduring prolonged waitlists for consultations, secure a semaglutide clinic appointment near you within a day through our practical telehealth platform
Typically, branded GLP-1s (Ozempic (semaglutide), Mounjaro (tirzepatide), Zepbound (tirzepatide), Saxenda (liraglutide)) are prescribed for people with obesity (a BMI over 30) or those who are overweight (a BMI over 25) and at least one related condition like diabetes or heart disease
Semaglutide makes you feel fuller faster, have fewer food cravings, and eat smaller meal portions
This allows for more efficient absorption and consistent results
